2009
Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells
Liu DV, Maier LM, Hafler DA, Wittrup KD. Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells. Journal Of Immunotherapy 2009, 32: 887-894. PMID: 19816193, PMCID: PMC4078882, DOI: 10.1097/cji.0b013e3181b528da.Peer-Reviewed Original ResearchConceptsIL-2 receptorRegulatory T cellsWild-type IL-2IL-2T cellsIL-2 analogHigh regulatory T cellsIL-2 receptor alphaRegulatory T-cell suppressionInterleukin-2 antagonistsAntitumor immune responseT cell suppressionIL-2 receptor alpha subunitT cell growthT cell linesTreg inhibitionImmunosuppressive effectsCancer patientsSimilar efficacyImmune responseReceptor alpha subunitCell suppressionReceptor alphaAlpha subunitHuman interleukin
2001
Heterophile Antibodies Indicate Progression of Autoimmunity in Human Type 1 Diabetes Mellitus Before Clinical Onset
Orban T, Kent SC, Malik P, Milner JD, Schuster K, Jackson RA, Hafler DA. Heterophile Antibodies Indicate Progression of Autoimmunity in Human Type 1 Diabetes Mellitus Before Clinical Onset. Autoimmunity 2001, 34: 247-264. PMID: 11905851, DOI: 10.3109/08916930109014694.Peer-Reviewed Original ResearchConceptsHeterophile antibodiesType 1 diabetes autoimmunityType 1 diabetes mellitus patientsDiabetes mellitus patientsProgression of autoimmunityAntibody-positive seraType 1 diabetesFirst-degree relativesHuman type 1T cell growthAnti-human immunoglobulinDiabetes autoimmunitySerum cytokinesMellitus patientsClinical onsetAntibody presenceIL-4Degree relativesDisease progressionLower incidenceHigh riskHigh incidenceHeterophilic antibodiesAntibody activityAntibody reactivity